Wockhardt Limited (NSE: WOCKPHARMA.NS) Stock Competitors & Peer Comparison

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, ABBOTINDIA.NS has a market cap of 531.9B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while ABBOTINDIA.NS trades at ₹25,030.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas ABBOTINDIA.NS's P/E ratio is 33.80. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to ABBOTINDIA.NS's ROE of +0.38%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to ABBOTINDIA.NS. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check ABBOTINDIA.NS's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, ABBOTINDIA.BO has a market cap of 531.3B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while ABBOTINDIA.BO trades at ₹25,004.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas ABBOTINDIA.BO's P/E ratio is 33.76. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to ABBOTINDIA.BO's ROE of +0.38%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to ABBOTINDIA.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check ABBOTINDIA.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, JBCHEPHARM.NS has a market cap of 387.9B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while JBCHEPHARM.NS trades at ₹2,416.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas JBCHEPHARM.NS's P/E ratio is 52.07. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to JBCHEPHARM.NS's ROE of +0.19%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to JBCHEPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check JBCHEPHARM.NS's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, JBCHEPHARM.BO has a market cap of 387.3B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while JBCHEPHARM.BO trades at ₹2,412.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas JBCHEPHARM.BO's P/E ratio is 50.89. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to JBCHEPHARM.BO's ROE of +0.19%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to JBCHEPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check JBCHEPHARM.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, WOCKPHARMA.BO has a market cap of 292.6B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while WOCKPHARMA.BO trades at ₹1,801.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas WOCKPHARMA.BO's P/E ratio is 71.56. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to WOCKPHARMA.BO's ROE of +0.08%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to WOCKPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check WOCKPHARMA.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, MEDPLUS.NS has a market cap of 71.5B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while MEDPLUS.NS trades at ₹595.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas MEDPLUS.NS's P/E ratio is 32.21. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to MEDPLUS.NS's ROE of +0.11%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to MEDPLUS.NS. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check MEDPLUS.NS's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, MEDPLUS.BO has a market cap of 71.5B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while MEDPLUS.BO trades at ₹593.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas MEDPLUS.BO's P/E ratio is 31.58. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to MEDPLUS.BO's ROE of +0.11%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to MEDPLUS.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check MEDPLUS.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, SUPRIYA.BO has a market cap of 65.8B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while SUPRIYA.BO trades at ₹818.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas SUPRIYA.BO's P/E ratio is 33.19. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to SUPRIYA.BO's ROE of +0.17%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to SUPRIYA.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check SUPRIYA.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, SUPRIYA.NS has a market cap of 65.3B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while SUPRIYA.NS trades at ₹818.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas SUPRIYA.NS's P/E ratio is 31.21. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to SUPRIYA.NS's ROE of +0.17%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to SUPRIYA.NS. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check SUPRIYA.NS's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, SANOFI.BO has a market cap of 63.9B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while SANOFI.BO trades at ₹2,775.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas SANOFI.BO's P/E ratio is 18.28. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to SANOFI.BO's ROE of +0.55%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to SANOFI.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check SANOFI.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, SANOFI.NS has a market cap of 63.9B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while SANOFI.NS trades at ₹2,772.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas SANOFI.NS's P/E ratio is 18.27. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to SANOFI.NS's ROE of +0.55%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to SANOFI.NS. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check SANOFI.NS's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, KPL.BO has a market cap of 36.6B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while KPL.BO trades at ₹3,531.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas KPL.BO's P/E ratio is 45.21. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to KPL.BO's ROE of +0.26%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to KPL.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check KPL.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, SHUKRAPHAR.BO has a market cap of 28.4B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while SHUKRAPHAR.BO trades at ₹64.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas SHUKRAPHAR.BO's P/E ratio is 83.33. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to SHUKRAPHAR.BO's ROE of +0.44%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to SHUKRAPHAR.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check SHUKRAPHAR.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, HIKAL.NS has a market cap of 23.9B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while HIKAL.NS trades at ₹193.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas HIKAL.NS's P/E ratio is 13.86. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to HIKAL.NS's ROE of -0.03%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to HIKAL.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check HIKAL.NS's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, HIKAL.BO has a market cap of 23.9B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while HIKAL.BO trades at ₹194.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas HIKAL.BO's P/E ratio is 169.35. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to HIKAL.BO's ROE of -0.03%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to HIKAL.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check HIKAL.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, FREDUN.BO has a market cap of 22.6B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while FREDUN.BO trades at ₹1,368.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas FREDUN.BO's P/E ratio is 53.84. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to FREDUN.BO's ROE of +0.20%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to FREDUN.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check FREDUN.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, ACCENTMIC.NS has a market cap of 14.2B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while ACCENTMIC.NS trades at ₹592.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas ACCENTMIC.NS's P/E ratio is 24.98. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to ACCENTMIC.NS's ROE of N/A. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to ACCENTMIC.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check ACCENTMIC.NS's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, BPLPHARMA.BO has a market cap of 11.5B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while BPLPHARMA.BO trades at ₹1,662.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas BPLPHARMA.BO's P/E ratio is -74.35. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to BPLPHARMA.BO's ROE of -0.05%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to BPLPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check BPLPHARMA.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, BAFNAPH.NS has a market cap of 10.5B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while BAFNAPH.NS trades at ₹442.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas BAFNAPH.NS's P/E ratio is 134.58. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to BAFNAPH.NS's ROE of +0.08%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to BAFNAPH.NS. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check BAFNAPH.NS's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, BAFNAPH.BO has a market cap of 10.5B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while BAFNAPH.BO trades at ₹449.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas BAFNAPH.BO's P/E ratio is 136.68. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to BAFNAPH.BO's ROE of +0.08%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to BAFNAPH.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check BAFNAPH.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, REMUS.NS has a market cap of 10.4B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while REMUS.NS trades at ₹880.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas REMUS.NS's P/E ratio is 28.05. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to REMUS.NS's ROE of N/A. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to REMUS.NS. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check REMUS.NS's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, VIKRAMTH.BO has a market cap of 9.8B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while VIKRAMTH.BO trades at ₹311.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas VIKRAMTH.BO's P/E ratio is 22.31. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to VIKRAMTH.BO's ROE of +0.30%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to VIKRAMTH.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check VIKRAMTH.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, SASTASUNDR.NS has a market cap of 9B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while SASTASUNDR.NS trades at ₹282.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas SASTASUNDR.NS's P/E ratio is 34.59. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to SASTASUNDR.NS's ROE of -0.03%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to SASTASUNDR.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check SASTASUNDR.NS's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, SGRL.BO has a market cap of 8B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while SGRL.BO trades at ₹625.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas SGRL.BO's P/E ratio is 52.04. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to SGRL.BO's ROE of +0.10%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to SGRL.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check SGRL.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, SUDARSHAN.BO has a market cap of 7.8B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while SUDARSHAN.BO trades at ₹31.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas SUDARSHAN.BO's P/E ratio is 29.50. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to SUDARSHAN.BO's ROE of +0.17%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to SUDARSHAN.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check SUDARSHAN.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, ONEGLOBAL.BO has a market cap of 7.4B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while ONEGLOBAL.BO trades at ₹367.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas ONEGLOBAL.BO's P/E ratio is 9.70. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to ONEGLOBAL.BO's ROE of +0.61%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to ONEGLOBAL.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check ONEGLOBAL.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, ALBERTDA.BO has a market cap of 6.2B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while ALBERTDA.BO trades at ₹1,084.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas ALBERTDA.BO's P/E ratio is 32.30. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to ALBERTDA.BO's ROE of +0.06%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to ALBERTDA.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check ALBERTDA.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, PRAVEG.BO has a market cap of 5.7B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while PRAVEG.BO trades at ₹219.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas PRAVEG.BO's P/E ratio is -30.29. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to PRAVEG.BO's ROE of -0.04%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to PRAVEG.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check PRAVEG.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, TRANSCHEM.BO has a market cap of 5.1B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while TRANSCHEM.BO trades at ₹418.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas TRANSCHEM.BO's P/E ratio is 111.07. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to TRANSCHEM.BO's ROE of +0.08%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to TRANSCHEM.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check TRANSCHEM.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, TLL.BO has a market cap of 4.9B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while TLL.BO trades at ₹407.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas TLL.BO's P/E ratio is 22.73. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to TLL.BO's ROE of +0.23%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to TLL.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check TLL.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, INFINIUM.NS has a market cap of 4.5B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while INFINIUM.NS trades at ₹286.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas INFINIUM.NS's P/E ratio is 36.68. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to INFINIUM.NS's ROE of N/A. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to INFINIUM.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check INFINIUM.NS's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, JENBURPH.BO has a market cap of 3.8B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while JENBURPH.BO trades at ₹860.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas JENBURPH.BO's P/E ratio is 11.56. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to JENBURPH.BO's ROE of +0.17%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to JENBURPH.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check JENBURPH.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, AMBALALSA.BO has a market cap of 2.7B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while AMBALALSA.BO trades at ₹34.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas AMBALALSA.BO's P/E ratio is 19.56. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to AMBALALSA.BO's ROE of +0.09%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to AMBALALSA.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check AMBALALSA.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, ZENOTECH.BO has a market cap of 2.5B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while ZENOTECH.BO trades at ₹40.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas ZENOTECH.BO's P/E ratio is -97.74. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to ZENOTECH.BO's ROE of -0.03%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to ZENOTECH.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check ZENOTECH.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, BDH.BO has a market cap of 2.4B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while BDH.BO trades at ₹423.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas BDH.BO's P/E ratio is 20.83. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to BDH.BO's ROE of +0.16%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to BDH.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check BDH.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, GENNEX.BO has a market cap of 2.1B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while GENNEX.BO trades at ₹8.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas GENNEX.BO's P/E ratio is 10.74. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to GENNEX.BO's ROE of +0.08%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to GENNEX.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check GENNEX.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, SANJIVIN.BO has a market cap of 1.9B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while SANJIVIN.BO trades at ₹152.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas SANJIVIN.BO's P/E ratio is 25.60. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to SANJIVIN.BO's ROE of +0.16%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to SANJIVIN.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check SANJIVIN.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, CORALAB.BO has a market cap of 1.8B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while CORALAB.BO trades at ₹494.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas CORALAB.BO's P/E ratio is 9.19. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to CORALAB.BO's ROE of +0.09%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to CORALAB.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check CORALAB.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, KERALAYUR.BO has a market cap of 1.7B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while KERALAYUR.BO trades at ₹131.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas KERALAYUR.BO's P/E ratio is -6.19. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to KERALAYUR.BO's ROE of -2.62%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to KERALAYUR.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check KERALAYUR.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, OXYGENTAPH.BO has a market cap of 1.7B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while OXYGENTAPH.BO trades at ₹46.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas OXYGENTAPH.BO's P/E ratio is -12.55. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to OXYGENTAPH.BO's ROE of +0.34%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to OXYGENTAPH.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check OXYGENTAPH.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, SYSCHEM.BO has a market cap of 1.7B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while SYSCHEM.BO trades at ₹31.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas SYSCHEM.BO's P/E ratio is 517.17. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to SYSCHEM.BO's ROE of +0.06%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to SYSCHEM.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check SYSCHEM.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, SMRUTHIORG.BO has a market cap of 1.5B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while SMRUTHIORG.BO trades at ₹133.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas SMRUTHIORG.BO's P/E ratio is 20.67. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to SMRUTHIORG.BO's ROE of +0.10%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to SMRUTHIORG.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check SMRUTHIORG.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, KIMIABL.BO has a market cap of 1.4B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while KIMIABL.BO trades at ₹29.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas KIMIABL.BO's P/E ratio is 19.75. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to KIMIABL.BO's ROE of +0.49%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to KIMIABL.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check KIMIABL.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, AUROLAB.BO has a market cap of 1.4B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while AUROLAB.BO trades at ₹212.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas AUROLAB.BO's P/E ratio is 29.12. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to AUROLAB.BO's ROE of +0.10%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to AUROLAB.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check AUROLAB.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, QUESTLAB.NS has a market cap of 1.3B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while QUESTLAB.NS trades at ₹82.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas QUESTLAB.NS's P/E ratio is 8.95. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to QUESTLAB.NS's ROE of N/A. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to QUESTLAB.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check QUESTLAB.NS's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, PARNAXLAB.BO has a market cap of 1.3B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while PARNAXLAB.BO trades at ₹111.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas PARNAXLAB.BO's P/E ratio is 14.37. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to PARNAXLAB.BO's ROE of +0.10%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to PARNAXLAB.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check PARNAXLAB.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, PANCHSHEEL.BO has a market cap of 1.3B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while PANCHSHEEL.BO trades at ₹96.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas PANCHSHEEL.BO's P/E ratio is 11.75. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to PANCHSHEEL.BO's ROE of +0.07%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to PANCHSHEEL.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check PANCHSHEEL.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, LACTOSE.BO has a market cap of 1.3B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while LACTOSE.BO trades at ₹99.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas LACTOSE.BO's P/E ratio is 18.08. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to LACTOSE.BO's ROE of +0.11%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to LACTOSE.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check LACTOSE.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, GODAVARI.BO has a market cap of 1.2B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while GODAVARI.BO trades at ₹120.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas GODAVARI.BO's P/E ratio is 27.70. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to GODAVARI.BO's ROE of +0.07%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to GODAVARI.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check GODAVARI.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, MAKERSL.BO has a market cap of 1.1B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while MAKERSL.BO trades at ₹192.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas MAKERSL.BO's P/E ratio is 33.14. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to MAKERSL.BO's ROE of +0.04%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to MAKERSL.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check MAKERSL.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, TYCHE.BO has a market cap of 1.1B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while TYCHE.BO trades at ₹104.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas TYCHE.BO's P/E ratio is 23.95. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to TYCHE.BO's ROE of +0.03%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to TYCHE.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check TYCHE.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, SOTAC.NS has a market cap of 1B. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while SOTAC.NS trades at ₹92.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas SOTAC.NS's P/E ratio is 17.61. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to SOTAC.NS's ROE of N/A. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to SOTAC.NS. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check SOTAC.NS's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, PHARMAID.BO has a market cap of 997.7M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while PHARMAID.BO trades at ₹28.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas PHARMAID.BO's P/E ratio is -21.87. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to PHARMAID.BO's ROE of -0.09%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to PHARMAID.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check PHARMAID.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, VAISHALI.NS has a market cap of 896.3M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while VAISHALI.NS trades at ₹6.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas VAISHALI.NS's P/E ratio is 21.40. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to VAISHALI.NS's ROE of +0.06%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to VAISHALI.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check VAISHALI.NS's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, MERCURYLAB.BO has a market cap of 877.3M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while MERCURYLAB.BO trades at ₹731.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas MERCURYLAB.BO's P/E ratio is 21.07. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to MERCURYLAB.BO's ROE of +0.07%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to MERCURYLAB.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check MERCURYLAB.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, DENISCHEM.BO has a market cap of 832.6M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while DENISCHEM.BO trades at ₹60.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas DENISCHEM.BO's P/E ratio is 10.43. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to DENISCHEM.BO's ROE of +0.09%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to DENISCHEM.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check DENISCHEM.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, CONCORD.BO has a market cap of 755.8M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while CONCORD.BO trades at ₹68.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas CONCORD.BO's P/E ratio is 40.51. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to CONCORD.BO's ROE of +0.05%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to CONCORD.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check CONCORD.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, SUNLOC.BO has a market cap of 717.8M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while SUNLOC.BO trades at ₹70.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas SUNLOC.BO's P/E ratio is 20.16. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to SUNLOC.BO's ROE of +0.05%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to SUNLOC.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check SUNLOC.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, VILINBIO.NS has a market cap of 710.8M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while VILINBIO.NS trades at ₹50.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas VILINBIO.NS's P/E ratio is 39.99. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to VILINBIO.NS's ROE of N/A. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to VILINBIO.NS. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check VILINBIO.NS's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, SOURCENTRL.BO has a market cap of 697.4M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while SOURCENTRL.BO trades at ₹108.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas SOURCENTRL.BO's P/E ratio is 20.52. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to SOURCENTRL.BO's ROE of +0.14%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to SOURCENTRL.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check SOURCENTRL.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, ZENITHDRUG.NS has a market cap of 676.5M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while ZENITHDRUG.NS trades at ₹39.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas ZENITHDRUG.NS's P/E ratio is 17.15. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to ZENITHDRUG.NS's ROE of N/A. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to ZENITHDRUG.NS. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check ZENITHDRUG.NS's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, PHRMASI.BO has a market cap of 600.6M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while PHRMASI.BO trades at ₹91.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas PHRMASI.BO's P/E ratio is 3.42. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to PHRMASI.BO's ROE of +1.07%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to PHRMASI.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check PHRMASI.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, SHELTER.BO has a market cap of 516.4M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while SHELTER.BO trades at ₹44.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas SHELTER.BO's P/E ratio is 8.27. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to SHELTER.BO's ROE of +0.13%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to SHELTER.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check SHELTER.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, PARMAX.BO has a market cap of 510.3M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while PARMAX.BO trades at ₹136.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas PARMAX.BO's P/E ratio is -44.29. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to PARMAX.BO's ROE of +0.22%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to PARMAX.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check PARMAX.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, ANG.BO has a market cap of 430.9M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while ANG.BO trades at ₹33.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas ANG.BO's P/E ratio is -3.23. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to ANG.BO's ROE of -0.23%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to ANG.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check ANG.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, VRL.BO has a market cap of 428.6M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while VRL.BO trades at ₹134.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas VRL.BO's P/E ratio is 7.40. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to VRL.BO's ROE of +0.15%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to VRL.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check VRL.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, BIBCL.BO has a market cap of 400.3M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while BIBCL.BO trades at ₹9.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas BIBCL.BO's P/E ratio is -3.66. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to BIBCL.BO's ROE of -0.17%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to BIBCL.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check BIBCL.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, MEDIORG.NS has a market cap of 365.3M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while MEDIORG.NS trades at ₹24.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas MEDIORG.NS's P/E ratio is -7.20. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to MEDIORG.NS's ROE of N/A. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to MEDIORG.NS. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check MEDIORG.NS's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, VISTAPH.BO has a market cap of 359.5M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while VISTAPH.BO trades at ₹5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas VISTAPH.BO's P/E ratio is -3.03. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to VISTAPH.BO's ROE of -0.27%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to VISTAPH.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check VISTAPH.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, ROOPAIND.BO has a market cap of 345M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while ROOPAIND.BO trades at ₹43.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas ROOPAIND.BO's P/E ratio is 337.38. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to ROOPAIND.BO's ROE of +0.01%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to ROOPAIND.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check ROOPAIND.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, SANDUPHQ.BO has a market cap of 328.4M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while SANDUPHQ.BO trades at ₹33.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas SANDUPHQ.BO's P/E ratio is 18.68. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to SANDUPHQ.BO's ROE of +0.04%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to SANDUPHQ.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check SANDUPHQ.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, MEDICAPQ.BO has a market cap of 311.7M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while MEDICAPQ.BO trades at ₹25.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas MEDICAPQ.BO's P/E ratio is -17.53. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to MEDICAPQ.BO's ROE of -0.02%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to MEDICAPQ.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check MEDICAPQ.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, PANJON.BO has a market cap of 301.4M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while PANJON.BO trades at ₹17.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas PANJON.BO's P/E ratio is 109.75. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to PANJON.BO's ROE of +0.04%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to PANJON.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check PANJON.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, DECCAN.BO has a market cap of 295.3M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while DECCAN.BO trades at ₹11.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas DECCAN.BO's P/E ratio is 11.70. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to DECCAN.BO's ROE of +0.02%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to DECCAN.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check DECCAN.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, BACPHAR.BO has a market cap of 286.8M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while BACPHAR.BO trades at ₹19.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas BACPHAR.BO's P/E ratio is 66.92. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to BACPHAR.BO's ROE of +0.02%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to BACPHAR.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check BACPHAR.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, GUJTERC.BO has a market cap of 265.9M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while GUJTERC.BO trades at ₹34.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas GUJTERC.BO's P/E ratio is 12.32. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to GUJTERC.BO's ROE of +0.24%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to GUJTERC.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check GUJTERC.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, TRIMURTHI.BO has a market cap of 264.8M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while TRIMURTHI.BO trades at ₹26.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas TRIMURTHI.BO's P/E ratio is 102.35. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to TRIMURTHI.BO's ROE of +0.10%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to TRIMURTHI.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check TRIMURTHI.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, WELCURE.BO has a market cap of 222.5M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while WELCURE.BO trades at ₹0.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas WELCURE.BO's P/E ratio is -8.94. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to WELCURE.BO's ROE of -0.34%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to WELCURE.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check WELCURE.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, ISHITADR.BO has a market cap of 209.4M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while ISHITADR.BO trades at ₹70.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas ISHITADR.BO's P/E ratio is 29.64. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to ISHITADR.BO's ROE of +0.06%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to ISHITADR.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check ISHITADR.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, CHEMOPH.BO has a market cap of 196.3M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while CHEMOPH.BO trades at ₹130.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas CHEMOPH.BO's P/E ratio is -1.61. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to CHEMOPH.BO's ROE of +0.03%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to CHEMOPH.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check CHEMOPH.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, ZENLABS.BO has a market cap of 175.4M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while ZENLABS.BO trades at ₹26.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas ZENLABS.BO's P/E ratio is -7.19. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to ZENLABS.BO's ROE of -0.27%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to ZENLABS.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check ZENLABS.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, COLINZ.BO has a market cap of 170M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while COLINZ.BO trades at ₹67.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas COLINZ.BO's P/E ratio is 6.08. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to COLINZ.BO's ROE of +0.28%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to COLINZ.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check COLINZ.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, NORRIS.BO has a market cap of 150.1M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while NORRIS.BO trades at ₹15.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas NORRIS.BO's P/E ratio is N/A. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to NORRIS.BO's ROE of +0.02%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to NORRIS.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check NORRIS.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, SHAMROIN.BO has a market cap of 147.9M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while SHAMROIN.BO trades at ₹27.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas SHAMROIN.BO's P/E ratio is -13.79. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to SHAMROIN.BO's ROE of -1.27%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to SHAMROIN.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check SHAMROIN.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, SUNREST.NS has a market cap of 143.8M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while SUNREST.NS trades at ₹33.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas SUNREST.NS's P/E ratio is 3.87. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to SUNREST.NS's ROE of N/A. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to SUNREST.NS. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check SUNREST.NS's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, BERLDRG.BO has a market cap of 125.2M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while BERLDRG.BO trades at ₹24.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas BERLDRG.BO's P/E ratio is 20.05. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to BERLDRG.BO's ROE of +0.07%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to BERLDRG.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check BERLDRG.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, EMMESSA.BO has a market cap of 105.1M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while EMMESSA.BO trades at ₹21.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas EMMESSA.BO's P/E ratio is 25.96. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to EMMESSA.BO's ROE of +0.05%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to EMMESSA.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check EMMESSA.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, KOBO.BO has a market cap of 97.7M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while KOBO.BO trades at ₹4.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas KOBO.BO's P/E ratio is -1.50. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to KOBO.BO's ROE of +0.04%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to KOBO.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check KOBO.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, ADLINE.BO has a market cap of 92.4M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while ADLINE.BO trades at ₹15.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas ADLINE.BO's P/E ratio is N/A. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to ADLINE.BO's ROE of N/A. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to ADLINE.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check ADLINE.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, GANGAPHARM.BO has a market cap of 73.9M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while GANGAPHARM.BO trades at ₹12.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas GANGAPHARM.BO's P/E ratio is 73.53. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to GANGAPHARM.BO's ROE of +0.01%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to GANGAPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check GANGAPHARM.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, TRINITYLEA.BO has a market cap of 73.7M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while TRINITYLEA.BO trades at ₹9.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas TRINITYLEA.BO's P/E ratio is -54.76. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to TRINITYLEA.BO's ROE of -0.05%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to TRINITYLEA.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check TRINITYLEA.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, HINDBIO.BO has a market cap of 70.7M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while HINDBIO.BO trades at ₹6.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas HINDBIO.BO's P/E ratio is -34.33. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to HINDBIO.BO's ROE of -0.24%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to HINDBIO.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check HINDBIO.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, TIAANC.BO has a market cap of 64.5M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while TIAANC.BO trades at ₹6.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas TIAANC.BO's P/E ratio is -48.31. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to TIAANC.BO's ROE of -0.01%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to TIAANC.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check TIAANC.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, VIVANZA.BO has a market cap of 64M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while VIVANZA.BO trades at ₹1.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas VIVANZA.BO's P/E ratio is 14.08. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to VIVANZA.BO's ROE of +0.10%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to VIVANZA.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check VIVANZA.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, DECIPHER.BO has a market cap of 51.3M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while DECIPHER.BO trades at ₹5.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas DECIPHER.BO's P/E ratio is -1.68. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to DECIPHER.BO's ROE of -0.09%. Regarding short-term risk, WOCKPHARMA.NS is less volatile compared to DECIPHER.BO. This indicates lower risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check DECIPHER.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, TMTIND-B1.BO has a market cap of 43.9M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while TMTIND-B1.BO trades at ₹8.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas TMTIND-B1.BO's P/E ratio is -177.40. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to TMTIND-B1.BO's ROE of N/A. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to TMTIND-B1.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check TMTIND-B1.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, FABINO.BO has a market cap of 42.7M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while FABINO.BO trades at ₹20.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas FABINO.BO's P/E ratio is -7.64. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to FABINO.BO's ROE of +0.01%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to FABINO.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check FABINO.BO's competition here

Wockhardt Limited (NSE: WOCKPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WOCKPHARMA.NS stands at 292.8B. In comparison, PATIDAR.BO has a market cap of 35.6M. Regarding current trading prices, WOCKPHARMA.NS is priced at ₹1,801.70 on the NSE, while PATIDAR.BO trades at ₹6.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WOCKPHARMA.NS currently has a P/E ratio of 71.58, whereas PATIDAR.BO's P/E ratio is -15.43. In terms of profitability, WOCKPHARMA.NS's ROE is +0.08%, compared to PATIDAR.BO's ROE of -0.03%. Regarding short-term risk, WOCKPHARMA.NS is more volatile compared to PATIDAR.BO. This indicates higher risk in terms of short-term price fluctuations for WOCKPHARMA.NS.Check PATIDAR.BO's competition here